Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression.

Abstract

BACKGROUND:

Treatment-emergent mania is a potential risk when patients with bipolar disorder are treated with antidepressant agents. These subanalyses compare treatment-emergent mania rates in bipolar I depressed patients treated with olanzapine, placebo, or olanzapine/fluoxetine combination.

METHOD:

In this 8-week, double-blind investigation, patients with bipolar I depression (DSM-IV criteria) (N = 833, baseline Montgomery-Asberg Depression Rating Scale total score > or = 20) were randomly assigned to olanzapine (5-20 mg/day, N = 370), placebo (N = 377), or olanzapine/fluoxetine combination (6/25, 6/50, or 12/50 mg/day; N = 86). Treatment-emergent mania was evaluated with the Young Mania Rating Scale (YMRS), the Clinical Global Impressions-Bipolar Edition (CGI-BP) Severity of Mania scale, and adverse events records.

RESULTS:

Overall rates of study discontinuation due to mania were low and not significantly different among the therapy groups (p = .358). Incidence of treatment-emergent mania (defined as a YMRS score < 15 at baseline and > or = 15 at any subsequent visit) did not differ significantly among therapy groups (olanzapine 5.7%, placebo 6.7%, olanzapine/fluoxetine combination 6.4%; p = .861). Subjects receiving olanzapine or olanzapine/fluoxetine combination had greater mean decreases in YMRS scores than those receiving placebo (p < .001 for both). Subjects receiving olanzapine or olanzapine/fluoxetine combination also had greater mean decreases in CGI-BP scores than those receiving placebo (p = .040 and p = .003, respectively).

CONCLUSION:

These results suggest that olanzapine/fluoxetine combination does not present a greater risk of treatment-emergent mania compared to olanzapine or placebo over 8 weeks of acute treatment for bipolar I depression. Due to the cyclical nature of bipolar disorder, patients taking olanzapine/fluoxetine combination for bipolar depression should still be monitored for signs or symptoms of emerging mania.

• Authors: Paul E Keck Jr, Sara A Corya, Lori L Altshuler, Terence A Ketter, Susan L McElroy, Michael Case, Susan D Briggs, Mauricio Tohen
• Journal: The Journal of clinical psychiatry (J Clin Psychiatry) Vol. 66 Issue 5 Pg. 611-6 (May 2005) ISSN: 0160-6689 [Print] United States
• PMID: 15889948 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antipsychotic Agents
• Placebos
• Serotonin Uptake Inhibitors
• Fluoxetine
• Benzodiazepines
• Olanzapine

Topics

• Adult
• Antipsychotic Agents (adverse effects, therapeutic use)
• Benzodiazepines (adverse effects, therapeutic use)
• Bipolar Disorder (chemically induced, diagnosis, drug therapy, psychology)
• Double-Blind Method
• Drug Therapy, Combination
• Female
• Fluoxetine (adverse effects, therapeutic use)
• Humans
• Male
• Olanzapine
• Placebos
• Psychiatric Status Rating Scales
• Risk Factors
• Selective Serotonin Reuptake Inhibitors (adverse effects, therapeutic use)
• Severity of Illness Index
• Treatment Outcome